ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The company is headquartered in Winston-Salem, North Carolina and currently employs 204 full-time employees. The firm is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. The company is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.
Follow-Up Questions
Qui est le CEO de ProKidney Corp ?
Dr. Bruce Culleton est le Chief Executive Officer de ProKidney Corp, il a rejoint l'entreprise depuis 2023.
Quelle est la performance du prix de l'action PROK ?
Le prix actuel de PROK est de $3.2, il a increased de 7.74% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de ProKidney Corp ?
ProKidney Corp appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de ProKidney Corp ?
La capitalisation boursière actuelle de ProKidney Corp est de $941.6M
Est-ce que ProKidney Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 8 analystes ont établi des notations d'analystes pour ProKidney Corp, y compris 5 achat fort, 4 achat, 4 maintien, 1 vente et 5 vente forte
